BACKGROUND: The objective of this study is to conduct a pooled analysis of National Surgical Adjuvant Breast and Bowel Project (NSABP) colon trials involving surgery and surgery plus 5-fluorouracil and leucovorin (5-FU/LV) to compare survival and establish a baseline from which to evaluate future studies. METHODS:All patients enrolled in NSABP adjuvant trials C-01 through C-05 with stage II and III disease who were treated with surgery or withsurgery plus 5-FU/LV were examined for overall survival (OS), disease-free survival (DFS), and recurrence-free interval (RFI). Time-to-event by treatment group was examined using adjusted Kaplan-Meier estimates and multivariable Cox regression analysis. RESULTS: There were 2,966 eligible patients: 693 (23%) surgery and 2,273 (77%) surgery plus 5-FU/LV; 1,255 (42%) stage II and 1,711 (58%) stage III. Age > or =60 years [hazard ratio (HR) = 1.36, P < 0.0001], male gender (HR = 1.20, P = 0.0012), and more nodes positive or fewer nodes examined (P < 0.0001) were associated with worse survival. At 5 years, the adjusted OS was 0.62 [confidence interval (CI) = 0.60-0.63] in the surgery group and 0.76 (CI = 0.74-0.78) in the surgery plus 5-FU/LV group. Treatment with 5-FU/LV was associated with improved outcome compared with surgery: OS (HR = 0.62, P < 0.0001), DFS (HR = 0.66, P < 0.0001) and RFI (HR = 0.64, P < 0.0001). Improved OS with adjuvant treatment was seen in both stage II (HR = 0.58, 95% CI = 0.48-0.71) and stage III disease (HR = 0.65, 95% CI = 0.55-0.75). CONCLUSIONS: This analysis demonstrates that treatment of colon cancer patients with5-FU/LV following surgery provides benefit over surgery alone and can provide anticipated survival outcomes with which to compare modern adjuvant trials.
RCT Entities:
BACKGROUND: The objective of this study is to conduct a pooled analysis of National Surgical Adjuvant Breast and Bowel Project (NSABP) colon trials involving surgery and surgery plus 5-fluorouracil and leucovorin (5-FU/LV) to compare survival and establish a baseline from which to evaluate future studies. METHODS: All patients enrolled in NSABP adjuvant trials C-01 through C-05 with stage II and III disease who were treated with surgery or with surgery plus 5-FU/LV were examined for overall survival (OS), disease-free survival (DFS), and recurrence-free interval (RFI). Time-to-event by treatment group was examined using adjusted Kaplan-Meier estimates and multivariable Cox regression analysis. RESULTS: There were 2,966 eligible patients: 693 (23%) surgery and 2,273 (77%) surgery plus 5-FU/LV; 1,255 (42%) stage II and 1,711 (58%) stage III. Age > or =60 years [hazard ratio (HR) = 1.36, P < 0.0001], male gender (HR = 1.20, P = 0.0012), and more nodes positive or fewer nodes examined (P < 0.0001) were associated with worse survival. At 5 years, the adjusted OS was 0.62 [confidence interval (CI) = 0.60-0.63] in the surgery group and 0.76 (CI = 0.74-0.78) in the surgery plus 5-FU/LV group. Treatment with 5-FU/LV was associated with improved outcome compared with surgery: OS (HR = 0.62, P < 0.0001), DFS (HR = 0.66, P < 0.0001) and RFI (HR = 0.64, P < 0.0001). Improved OS with adjuvant treatment was seen in both stage II (HR = 0.58, 95% CI = 0.48-0.71) and stage III disease (HR = 0.65, 95% CI = 0.55-0.75). CONCLUSIONS: This analysis demonstrates that treatment of colon cancerpatients with 5-FU/LV following surgery provides benefit over surgery alone and can provide anticipated survival outcomes with which to compare modern adjuvant trials.
Authors: N Wolmark; H Rockette; E Mamounas; J Jones; S Wieand; D L Wickerham; H D Bear; J N Atkins; N V Dimitrov; A G Glass; E R Fisher; B Fisher Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: Jukes Namm; Melody Ng; Sharmila Roy-Chowdhury; John W Morgan; Sharon S Lum; Jan H Wong Journal: J Am Coll Surg Date: 2008-10-02 Impact factor: 6.113
Authors: C C Earle; M R Weiser; A Ter Veer; J M Skibber; J Wilson; A Rajput; Y N Wong; A B Benson; S Shibata; D Romanus; J Niland; D Schrag Journal: J Surg Oncol Date: 2009-12-01 Impact factor: 3.454
Authors: N Wolmark; B Fisher; H Rockette; C Redmond; D L Wickerham; E R Fisher; J Jones; A Glass; H Lerner; W Lawrence Journal: J Natl Cancer Inst Date: 1988-03-02 Impact factor: 13.506
Authors: Vassiliki L Tsikitis; David L Larson; Bruce G Wolff; Gregory Kennedy; Nancy Diehl; Rui Qin; Eric J Dozois; Robert R Cima Journal: J Am Coll Surg Date: 2009-01 Impact factor: 6.113
Authors: Daniel Sargent; Alberto Sobrero; Axel Grothey; Michael J O'Connell; Marc Buyse; Thierry Andre; Yan Zheng; Erin Green; Roberto Labianca; Chris O'Callaghan; Jean Francois Seitz; Guido Francini; Daniel Haller; Greg Yothers; Richard Goldberg; Aimery de Gramont Journal: J Clin Oncol Date: 2009-01-05 Impact factor: 44.544
Authors: René Adam; Dennis A Wicherts; Robbert J de Haas; Thomas Aloia; Francis Lévi; Bernard Paule; Catherine Guettier; Francis Kunstlinger; Valérie Delvart; Daniel Azoulay; Denis Castaing Journal: J Clin Oncol Date: 2008-04-01 Impact factor: 44.544
Authors: Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg Journal: J Clin Oncol Date: 2004-04-05 Impact factor: 44.544
Authors: Nader N Massarweh; Alex B Haynes; Yi-Ju Chiang; George J Chang; Y Nancy You; Barry W Feig; Janice N Cormier Journal: Ann Surg Date: 2015-08 Impact factor: 12.969
Authors: Christina E Bailey; Chung-Yuan Hu; Y Nancy You; Harmeet Kaur; Randy D Ernst; George J Chang Journal: J Oncol Pract Date: 2015-04-07 Impact factor: 3.840
Authors: Manuel Valdivieso; Benjamin W Corn; Janet E Dancey; D Lawrence Wickerham; L Elise Horvath; Edith A Perez; Alison Urton; Walter M Cronin; Erica Field; Evonne Lackey; Charles D Blanke Journal: Semin Oncol Date: 2015-07-10 Impact factor: 4.929
Authors: Genevieve M Boland; George J Chang; Alex B Haynes; Yi-Ju Chiang; Ryaz Chagpar; Yan Xing; Chung-Yuan Hu; Barry W Feig; Y Nancy You; Janice N Cormier Journal: Cancer Date: 2012-12-21 Impact factor: 6.860